Loading
Ferroptosis and Cancer Prognosis · Journal article
Discover Oncology · September 5, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a retrospective bioinformatic study that identified a six-gene risk signature (AHNAK2, ARHGAP32, EVL, PRKCI, PTGES, S100A16) derived from TPM1-positive myofibroblastic cancer-associated fibroblasts and constructed a prognostic risk model and nomogram. The authors report the model showed promise in prognostic performance but explicitly acknowledge that further validation in diverse clinical subgroups and examination of generalizability across patient populations are needed.
Retrospective integrative bioinformatic analysis of public single-cell and bulk RNA-seq datasets. Pancreatic cancer patients represented in GSE197177 scRNA-seq dataset and TCGA-PAAD bulk RNA-seq cohort. Specific inclusion/exclusion criteria and demographic details not provided.. Intervention: TPM1-positive myofibroblastic cancer-associated fibroblasts (myCAFs) and six-gene risk model based on prognostic gene signature (AHNAK2, ARHGAP32, EVL, PRKCI, PTGES, S100A16).
Six prognostic genes (AHNAK2, ARHGAP32, EVL, PRKCI, PTGES, S100A16) identified from TPM1+ myCAF subtype Regulatory factors DPF2 and hsa-miR-107 predicted to target prognostic genes Risk scores associated with cell cycle pathway, infiltration of T follicular helper cells, immune checkpoint blockade response, and lapatinib sensitivity
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
If validated prospectively, this risk model could support pancreatic cancer prognostication and guide immunotherapy or targeted drug selection. Current evidence is insufficient to change clinical practice; the model requires independent external validation and assessment in diverse patient subgroups before clinical deployment.
This is a retrospective computational study integrating public datasets to construct a prognostic risk model; it lacks independent prospective validation and the authors explicitly state the model requires further validation in diverse clinical subgroups and across patient populations.
As stated by the source record.
If validated prospectively, this risk model could support pancreatic cancer prognostication and guide immunotherapy or targeted drug selection. Current evidence is insufficient to change clinical practice; the model requires independent external validation and assessment in diverse patient subgroups before clinical deployment.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Pancreatic cancer (PC) has a poor prognosis, and treatment is largely ineffective because of its unique tumor microenvironment (TME). We identified key cell types in PC using the GSE197177 dataset generated through single-cell RNA sequencing (scRNA-seq) analysis. Using TCGA-PAAD data, prognosis-related cell subtypes were identified by BayesPrism and Cox regression. Hub cell subtype-related prognostic genes were screened by integrating high-dimensional weighted gene co-expression network analysis (hdWGCNA), differential expression analysis, univariate Cox regression, and least absolute shrinkage and selection operator (LASSO) regression. The upstream regulatory factors of prognostic genes were predicted. A risk model and nomogram were generated and validated, with risk scores used to evaluate pathways, the TME, immunotherapy, and drug sensitivity. Fibroblasts were identified as the key cell type in PC. TPM1 + myofibroblastic cancer-associated fibroblasts (CAFs) (myCAFs) were considered the prognosis-related hub cell subtype. AHNAK2, ARHGAP32, EVL, PRKCI, PTGES, and S100A16 were identified as prognostic genes. Regulatory factors, including DPF2 and hsa-miR-107, were predicted to target the prognostic genes. The constructed risk model and nomogram showed promise in prognostic performance, although further validation in diverse clinical subgroups is needed. Risk scores were associated with pathways, including the cell cycle, infiltration of immune cell types such as T follicular helper cells, response to immune checkpoint blockade therapy, and sensitivity to drugs such as lapatinib. A risk model based on six TPM1 + myCAF-related prognostic genes was constructed, which exhibited robust predictive ability. Our results provide novel insights into TPM1 + myCAF-related mechanisms and PC prognostic prediction, although the model’s generalizability to all patient subgroups requires further examination.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.